Acazicolcept is under clinical development by Alpine Immune Sciences and currently in Phase I for Uveitis. According to GlobalData, Phase I drugs for Uveitis have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Acazicolcept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acazicolcept is under development for the treatment of multiple sclerosis, arthritis, inflammatory bowel disease, hemophagocytic lymphohistiocytosis, sicca syndrome (sjogren), uveitis, type I diabetes, systemic lupus erythematosus. It acts by targeting inducible T-cell costimulator (ICOS) and T cell-specific surface glycoprotein CD28 (CD28). It is administered by intravenous or subcutaneous routes as an injection. The drug candidate is developed based on the variant immunoglobulin domain (vIgD) platform technology. It is a fusion protein, synthesized by combining vIgDs with antibody Fc domains.
It was also under development for psoriatic arthritis, graft versus host disease (GVHD) and rheumatoid arthritis.
Alpine Immune Sciences overview
Alpine Immune Sciences (Alpine), formerly Nivalis Therapeutics Inc, is a pharmaceutical company. The company focuses on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. It provides ALPN-101 and ALPN-303 for the treatment of based immunotherapies and immune synapses to treat cancer and autoimmune and inflammatory diseases. The company also provides ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer. It offers a proprietary scientific platform that converts native immune system proteins into differentiated, multi-targeted therapeutics. Alpine is headquartered in Seattle, Washington, the US.
For a complete picture of Acazicolcept’s drug-specific PTSR and LoA scores, buy the report here.